{"query": "What ECOG performance status must participants have for trial NCT06556563?", "nct_id": "NCT06556563", "answers": ["Have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1 assessed within 7 days before randomization."], "sections": ["eligibility.inclusion"]}
{"query": "What measurable disease requirement does NCT02586857 enforce?", "nct_id": "NCT02586857", "answers": ["Measurable disease (bidimensional) as defined by the RANO criteria, with a minimum measurement of 1 cm in longest diameter on MRI performed within 21 days of first dose of acalabrutinib; MRI must have been obtained ≥4 weeks after any salvage surgery after first or second relapse."], "sections": ["eligibility.inclusion"]}
{"query": "Which anticoagulant therapies exclude someone from NCT06051214?", "nct_id": "NCT06051214", "answers": ["Patient on low molecular weight heparins, standard unfractionated heparins and anti-vitamin K2"], "sections": ["eligibility.exclusion"]}
{"query": "How many biopsy samples must be obtainable during surgery in NCT05386043?", "nct_id": "NCT05386043", "answers": ["Subject has sufficient tissue so that the study team is able to acquire at least 2 biopsy samples during resection."], "sections": ["eligibility.inclusion"]}
{"query": "Name the STAT3-targeting drug administered in NCT05879250.", "nct_id": "NCT05879250", "answers": ["STAT3 Inhibitor WP1066", "WP1066"], "sections": ["interventions"]}
{"query": "Which BRAF alterations qualify participants for MATCH subprotocol Z1L (NCT06400225)?", "nct_id": "NCT06400225", "answers": ["Patients must have a BRAF non-V600 mutation or BRAF fusion, or another BRAF aberration, as determined via the MATCH Master Protocol"], "sections": ["eligibility.inclusion"]}
{"query": "What tissue availability is required before enrolling in NCT03529448?", "nct_id": "NCT03529448", "answers": ["Patients must have at least 15 slides without staining or a tissue block (frozen or paraffin-embedded) available from a previous biopsy or surgery (tumour sample previously archived)."], "sections": ["eligibility.inclusion"]}
{"query": "Which condition does trial NCT05118776 focus on?", "nct_id": "NCT05118776", "answers": ["Recurrent Glioblastoma"], "sections": ["condition"]}
{"query": "In trial NCT06989086, who can enroll as caregivers?", "nct_id": "NCT06989086", "answers": ["Caregivers: nonprofessional caregiver to a patient with a primary malignant brain tumor (grade II-IV)", "nonprofessional caregiver to a patient with a primary malignant brain tumor (grade II-IV)"], "sections": ["eligibility.inclusion"]}
{"query": "What biomarker testing is required in NCT04765514 before randomization?", "nct_id": "NCT04765514", "answers": ["MGMT promoter methylation status must be tested for all patients."], "sections": ["eligibility.inclusion"]}
{"query": "What outcome measure tracks the MRI sequence program in NCT06041555?", "nct_id": "NCT06041555", "answers": ["Hypoxia mapping"], "sections": ["outcomes"]}
{"query": "Which drug is paired with radiodynamic therapy in NCT05590689?", "nct_id": "NCT05590689", "answers": ["DRUG: Gliolan", "Gliolan"], "sections": ["interventions"]}
{"query": "What hypofractionated approach is being tested against conventional radiotherapy in NCT06740955?", "nct_id": "NCT06740955", "answers": ["RADIATION: hypofractionated postoperative radiotherapy"], "sections": ["interventions"]}
{"query": "For NCT03451799, how long is safety of the ketogenic diet monitored?", "nct_id": "NCT03451799", "answers": ["Four Months", "Four months"], "sections": ["outcomes"]}
{"query": "What tumor grades must be documented for eligibility in NCT06275919?", "nct_id": "NCT06275919", "answers": ["Histological diagnosis of grade 2 or grade 3 meningioma according to the WHO 2021 classification"], "sections": ["eligibility.inclusion"]}
{"query": "Which radiation technique is delivered upfront in NCT03251027?", "nct_id": "NCT03251027", "answers": ["RADIATION: Intensity-Modulated Radiation Therapy"], "sections": ["interventions"]}
{"query": "What confirmation is required before administering the DRI γδ T cell injection in NCT04165941?", "nct_id": "NCT04165941", "answers": ["Must have histologically or cytologically confirmed glioblastoma multiforme prior to administration of the DRI γδ T cell injection."], "sections": ["eligibility.inclusion"]}
{"query": "Which PET tracer is collected as part of the imaging regimen in NCT06113705?", "nct_id": "NCT06113705", "answers": ["DIAGNOSTIC_TEST: 18F-GE-180 PET", "18F-GE-180 PET"], "sections": ["interventions"]}
{"query": "What biomarker must patients carry to join NCT06308822?", "nct_id": "NCT06308822", "answers": ["Patients must have FGFR Amplification as determined via the MATCH Master Protocol."], "sections": ["eligibility.inclusion"]}
{"query": "Which diagnosis leads to exclusion from NCT04306432?", "nct_id": "NCT04306432", "answers": ["Glioblastoma"], "sections": ["eligibility.exclusion"]}
{"query": "What is the official title of NCT04440358?", "nct_id": "NCT04440358", "answers": ["Assessment of Safety and Feasibility of Exablate Blood-Brain Barrier Disruption (BBBD) With Microbubbles for the Treatment of Recurrent Glioblastoma (rGBM) in Subjects Undergoing Carboplatin Monotherapy"], "sections": ["title"]}
